Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Beijer Byggmaterial in connection with entering into an agreement to acquire PoG Woody Bygghandel
Mandate

Vinge has advised Beijer Byggmaterial in connection with entering into an agreement to acquire PoG Woody Bygghandel

June 25, 2019 M&A

Vinge has advised Beijer Byggmaterial AB (“Beijer Byggmaterial”) in connection with Beijer Byggmaterial entering into an agreement to acquire PoG Woody Bygghandel AB. Completion of the transaction is subject to customary conditions. 

PoG Woody Bygghandel AB is a strong regional player operating six branches including a distribution centre in the south of Sweden, which is an important growth centre for the building materials supply industry. Beijer Byggmaterial is part of Stark Group, the largest retailer and distributor of building materials in the Nordic region with operations in Denmark, Greenland, Norway, Sweden and Finland.

Vinge’s team consisted of, among others, Jonas Bergström, Linda Sengul, Anna Thoms and Vilhelm Rondahl (M&A), Michael Montner (Corporate Commercial), Kristoffer Larsson (Real Property/Lease Agreements) and Sebastian Örndahl (Anti Trust).
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024